X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Pharma was blindsided last week by the plan to index certain expensive drugs paid for by Medicare to much lower international prices. (Photo: Getty)

Earnings are now in at most of the biggest pharmaceutical firms, and one thing is clear from their results: One of President Donald Trump’s most visible efforts to strong-arm them on prices hasn’t caused much pain.

BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now

Copyright © 2018 ALM Media Properties, LLC. All Rights Reserved.